Resumo

MONTOYA, F. et al. Non-interventional multicenter study in patients with arthritis rheumatoid treated with tocilizumab. Rev. argent. reumatolg. [online]. 2017, vol.28, n.3, pp.23-28. ISSN 0327-4411.

Introduction: Tocilizumab is a monoclonal antibody against IL-6 receptor that has shown efficacy and safety in rheumatoid arthritis (RA). Methods and objectives: Observational cohort study in patients with moderate to severe RA treated with tocilizumab during 6 months. The primary objective was to establish the adherence of treatment and second to study its effectiveness and safety. Results: 50 patients were treated with tocilizumab (86% in combination with DMARDs and 14% as monotherapy). The adherence to treatment was 42/50 (84%; 95% CI: 71-93%) and the proportion of response according to ACR criteria 20/50/70/90 was 68.2%, 40.9%, 13.6% and 9.1% respectively. The 28 joint count with tenderness (TJC28) and swelling (SJC28) was significantly reduced from 12/8 at baseline to 5/2 at 6 months respectively (p <0.001). We observed a significant reduction in physician assessment of activity and in patient reported outcomes. No adverse events of severe intensity or serious adverse events according to regulatory criteria related to study drug were reported. Conclusions: We observed that 42/50 patients adhered to treatment with significant response in the effectiveness parameters and adequate safety profile that are consistent with previously published studies.

Palavras-chave : tocilizumab; rheumatoid arthritis; monoclonal antibody.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )